BRAF and thyroid cancer: In thyroid cancer, SLC1A5 is reported to be expressed in only tumor cells and related to the BRAF V600E mutation, which is associated with extrathyroidal extension, advanced TNM stage, lymph node metastasis, multifocality and recurrence38.